

15 May 2018

ASX Limited
Level 6, Exchange Centre
20 Bridge Street
Sydney NSW 2000

**NOXOPHARM LIMITED (“NOX”)
Results of General Meeting (“GM”) of Members – 15 May 2018**

We advise that:

A. A summary of valid and eligible proxies received for the above meeting was as follows:

Resolution No and Type	Resolution Item	Proxy Results					
		For	Against	Abstain	Valid Open Proxy's Discretion ***	Invalid/ Excluded/ Open unusable **	Total *
1 Ordinary	Resolution 1 Approval of prior issue of shares to sophisticated and professional investors under ASX Listing Rule 7.4	48,831,834	51,054	-	39,505	4,695,859	53,618,252
2 Ordinary	Resolution 2 Approval of share placement to sophisticated and professional investors under ASX Listing Rule 7.1	48,831,834	51,054	-	39,505	4,695,859	53,618,252

* There were no invalid votes.

** There were no votes in the “votes excluded / no instruction” column in the table above where the nominee registered shareholder had not received instructions from the beneficial shareholder. The votes in this column are votes unable to be cast due to voting restrictions as outlined in the Notice of Meeting.

*** Of the ‘undirected votes’, all votes except for 15,000 votes for Resolutions 1 and 2 (inclusive) were cast with the Chair as proxy, which as outlined in the Notice of Meeting would be voted FOR all resolutions.

B. The following resolutions were passed without resort to a poll at the GM of NOX on 15 May 2018.

Resolution 1:

Approval of prior issue of shares to sophisticated and professional investors under ASX Listing Rule 7.4

The motion was *carried* as an ordinary resolution on a show of hands.

Resolution 2:

Approval of share placement to sophisticated and professional investors under ASX Listing Rule 7.1

The motion was *carried* as an ordinary resolution on a show of hands.

Yours Sincerely



David Franks
Company Secretary
Noxopharm Limited

For further information, please contact:

David Franks
P: +61 2 9299 9690
E: dfranks@fa.com.au

ABOUT NOXOPHARM LIMITED

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product.